Please login to the form below

Not currently logged in
Email:
Password:

licence deal

This page shows the latest licence deal news and features for those working in and with pharma, biotech and healthcare.

Biogen picks up another drug from wide-ranging Ionis alliance

Biogen picks up another drug from wide-ranging Ionis alliance

The drug isn’t from that extension, rather it stems from an earlier licence deal between the companies dating back to 2013. ... Under the terms of the deal, Ionis receives $35m upfront and is eligible for another $55m in milestones, plus royalties up

Latest news

  • Otsuka licenses Lundbeck’s Alzheimer's drug in $825m deal Otsuka licenses Lundbeck’s Alzheimer's drug in $825m deal

    Japanese pharma company Otsuka has licensed an Alzheimer's disease drug candidate from Lundbeck in a deal that expands an ongoing collaboration between the two companies to include a third drug.

  • AZ moves to strengthen diabetes, cancer pipelines

    Tokyo-based Prosidion has already advanced the lead compound in the licence deal - called PSN821 - into phase II testing, while AstraZeneca has also take an option for a follow-up (PSN842) ... AstraZeneca has paid Prosidion an undisclosed option fee

  • Eastern Europe targeted

    The largest licence deal in May, financially, was that reported between Glenmark and Sanofi. ... COPD). As Almirall will be developing its own brand, this deal is more like a licence and as such commanded an undisclosed upfront fee.

  • FDA places hold on AIDS drug

    The US FDA has placed a clinical hold on an experimental HIV/AIDS drug being developed by GSK under a licence from Idenix Pharmaceuticals. ... Idenix has so far received $60.5m in licence fees under the deal and is eligible to receive up to $390m in

  • Novartis buys Ablynx Nanobody licences

    The licence acquisition is part of a deal between the two companies made in 2005 where Ablynx and Novartis agreed to collaborate in the research and development of Nanobody based therapeutics ... This deal was extended last year, and includes R&D payments

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... The deal also includes a licence to

  • Deal Watch October 2016 Deal Watch October 2016

    Astellas has structured its deal almost like a licence with one third of the consideration ($462m) upfront and the remainder in “further contingent milestones” (milestones and possibly royalties) as the product ... The licence deal obtained by Summit

  • Deal Watch May 2016 Deal Watch May 2016

    Building on its 2014 deal with MacroGenics, J&J entered into a licence and collaboration agreement for MGD015 for B-cell malignancies with an upfront fee of $75m and $665m in ... Another deal which has taken a hybrid licence / acquisition format is that

  • Deal Watch January 2016 Deal Watch January 2016

    The original deal was a worldwide exclusive licence for the commercialisation of Afrezza in diabetes, with expected peak sales in the range of $0.6bn to $1.0bn (the first nine ... Licensor/Acquired Acquiror/Partner. Deal Type. Comments. Hline $m. Baxalta/

  • Pharma deals in July 2015 Pharma deals in July 2015

    Biogen also broke the $1bn headline in a licence and collaboration deal with AGTC for gene based therapies to treat ophthalmic diseases. ... A strange coincidence! Licensor/Licensee Acquired / Acquirer. Deal type. Product/Technology. Headline $m.

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics